• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童及青少年C3肾小球病或免疫复合物膜增生性肾小球肾炎的肾移植:当前实践的国际调查

Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice.

作者信息

Patry Christian, Webb Nicholas J A, Meier Matthias, Pape Lars, Fichtner Alexander, Höcker Britta, Tönshoff Burkhard

机构信息

Department of Pediatrics I, University Children's Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.

Novartis Pharma AG, Basel, Switzerland.

出版信息

Pediatr Transplant. 2025 Mar;29(2):e70048. doi: 10.1111/petr.70048.

DOI:10.1111/petr.70048
PMID:39989336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11848702/
Abstract

BACKGROUND

Approximately 50% of patients with chronic kidney disease due to C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) will require dialysis and/or kidney transplantation (KTx) within the first 10 years of disease onset. Currently, there are no guidelines regarding the indications for KTx or post-transplant management.

METHODS

We therefore initiated an international online survey via Survey Monkey on C3G and IC-MPGN in children with CKD stage 5. All KTx centers of the European Society for Paediatric Nephrology (ESPN) were invited to participate in the survey, which was conducted from August 23 to November 25, 2023.

RESULTS

Sixty-five (63%) of the centers (n = 103) participated. Twenty-six percent had made at least one decision against living donation for a child with C3G or IC-MPGN. The main reason for 88.2% of these decisions was concern about the recurrence of the underlying disease in any potential transplant. Eighty-eight percent indicated deceased donation as an option; 12% decided not to proceed with transplantation at all. Regarding KTx decision-making or management, none of them referred to an existing recommendation by any national or regional guideline. For the recurrence of C3G or IC-MPGN post-transplant, eculizumab treatment was suggested by 60% of respondents.

CONCLUSION

This survey shows a considerable reluctance of pediatric nephrologists to list patients with CKD stage 5 due to C3G or IC-MPGN for living donor kidney transplantation. This decision is mainly based on the fear of recurrence of the underlying disease combined with the lack of reliable treatment options. This limited access of affected patients to the best treatment option for kidney failure requires further action.

摘要

背景

约50%因C3肾小球病(C3G)或原发性免疫复合物膜增生性肾小球肾炎(IC-MPGN)导致慢性肾脏病的患者在疾病发作后的前10年内需要透析和/或肾移植(KTx)。目前,尚无关于KTx适应症或移植后管理的指南。

方法

因此,我们通过Survey Monkey对5期慢性肾脏病儿童的C3G和IC-MPGN开展了一项国际在线调查。邀请了欧洲儿科肾脏病学会(ESPN)的所有KTx中心参与该调查,调查于2023年8月23日至11月25日进行。

结果

103个中心中有65个(63%)参与。26%的中心至少做出过一次反对为患有C3G或IC-MPGN的儿童进行活体捐赠的决定。这些决定中88.2%的主要原因是担心任何潜在移植中基础疾病的复发。88%的中心表示接受 deceased捐赠作为一种选择;12%的中心决定完全不进行移植。关于KTx决策或管理,没有一个中心参考任何国家或地区指南的现有建议。对于移植后C3G或IC-MPGN的复发,60%的受访者建议使用依库珠单抗治疗。

结论

这项调查显示,儿科肾脏病医生相当不愿意将因C3G或IC-MPGN导致5期慢性肾脏病的患者列入活体供肾移植名单。这一决定主要基于对基础疾病复发的担忧以及缺乏可靠的治疗选择。受影响患者获得肾衰竭最佳治疗选择的机会有限,这需要进一步采取行动。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af07/11848702/b6d5049e6261/PETR-29-e70048-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af07/11848702/db543a03821c/PETR-29-e70048-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af07/11848702/b6d5049e6261/PETR-29-e70048-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af07/11848702/db543a03821c/PETR-29-e70048-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af07/11848702/b6d5049e6261/PETR-29-e70048-g001.jpg

相似文献

1
Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice.儿童及青少年C3肾小球病或免疫复合物膜增生性肾小球肾炎的肾移植:当前实践的国际调查
Pediatr Transplant. 2025 Mar;29(2):e70048. doi: 10.1111/petr.70048.
2
Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.儿童和青少年 C3 肾小球病或免疫复合物性膜增生性肾小球肾炎患者的肾移植:CERTAIN 研究网络中的真实世界研究。
Pediatr Nephrol. 2024 Dec;39(12):3569-3580. doi: 10.1007/s00467-024-06476-5. Epub 2024 Aug 7.
3
Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.儿童和青少年膜增生性肾小球肾炎和 C3 肾小球病的结局。
Pediatr Nephrol. 2018 Dec;33(12):2289-2298. doi: 10.1007/s00467-018-4034-z. Epub 2018 Sep 20.
4
Clinical characteristics and short term outcomes of childhood immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy: a single centre retrospective study.儿童免疫复合物型膜增生性肾小球肾炎和C3肾小球病的临床特征及短期预后:一项单中心回顾性研究
BMC Nephrol. 2025 Mar 22;26(1):143. doi: 10.1186/s12882-025-04078-3.
5
Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.日本儿童免疫复合物性膜增生性肾小球肾炎和 C3 肾小球病的临床特征和转归。
Pediatr Nephrol. 2024 Sep;39(9):2679-2689. doi: 10.1007/s00467-024-06377-7. Epub 2024 Apr 25.
6
Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.C3肾小球病和原发性免疫复合物介导的膜增生性肾小球肾炎患者的移植结局。
Kidney Int Rep. 2024 Oct 15;10(1):75-86. doi: 10.1016/j.ekir.2024.10.008. eCollection 2025 Jan.
7
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.补体替代途径自身免疫异常在膜增生性肾小球肾炎和 C3 肾小球病中的作用。
Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9.
8
Clinical features and outcomes of immune complex-membranoproliferative glomerulonephritis and C3 glomerulopathy: a multicenter observational cohort study analyzing kidney biopsy cases.免疫复合物型膜增生性肾小球肾炎和C3肾小球病的临床特征及转归:一项分析肾活检病例的多中心观察性队列研究
Kidney Res Clin Pract. 2024 Dec 20. doi: 10.23876/j.krcp.24.129.
9
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.儿童 C3 肾小球病及相关疾病:病因-表型相关性和结局。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1639-1651. doi: 10.2215/CJN.00320121. Epub 2021 Sep 22.
10
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.膜增生性肾小球肾炎:不再是同一种疾病,可能需要非常不同的治疗。
Nephrol Dial Transplant. 2023 Feb 13;38(2):283-290. doi: 10.1093/ndt/gfab281.

引用本文的文献

1
Kidney and Bladder Transplantation: Advances, Barriers, and Emerging Solutions.肾脏与膀胱移植:进展、障碍及新出现的解决方案
Medicina (Kaunas). 2025 Jun 5;61(6):1045. doi: 10.3390/medicina61061045.

本文引用的文献

1
Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.儿童和青少年 C3 肾小球病或免疫复合物性膜增生性肾小球肾炎患者的肾移植:CERTAIN 研究网络中的真实世界研究。
Pediatr Nephrol. 2024 Dec;39(12):3569-3580. doi: 10.1007/s00467-024-06476-5. Epub 2024 Aug 7.
2
Prognosis is still poor in patients with posttransplant C3 glomerulopathy despite eculizumab use.尽管使用了依库珠单抗,但移植后C3肾小球病患者的预后仍然很差。
Clin Kidney J. 2024 Jun 20;17(7):sfae190. doi: 10.1093/ckj/sfae190. eCollection 2024 Jul.
3
Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.
肾移植中 C3 肾小球病的研究进展:发病机制与治疗选择。
Int J Mol Sci. 2024 Jun 13;25(12):6508. doi: 10.3390/ijms25126508.
4
Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.在肾移植后复发性C3肾小球病中使用依他库帕抑制补体B因子:两例报告
Kidney Med. 2024 Apr 12;6(6):100823. doi: 10.1016/j.xkme.2024.100823. eCollection 2024 Jun.
5
C3 Glomerulopathy: Novel Treatment Paradigms.C3肾小球病:新的治疗模式
Kidney Int Rep. 2023 Dec 16;9(3):569-579. doi: 10.1016/j.ekir.2023.12.007. eCollection 2024 Mar.
6
Recurrent C3 glomerulopathy after kidney transplantation.移植肾后复发性 C3 肾小球病。
Transplant Rev (Orlando). 2024 Apr;38(2):100839. doi: 10.1016/j.trre.2024.100839. Epub 2024 Feb 21.
7
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.依他卡帕对C3肾小球病患者的疗效和安全性
Kidney Int Rep. 2023 Sep 22;8(12):2754-2764. doi: 10.1016/j.ekir.2023.09.017. eCollection 2023 Dec.
8
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.用iptacopan抑制替代补体途径治疗C3肾小球病——APPEAR-C3G试验的研究设计
Kidney Int Rep. 2022 Aug 2;7(10):2150-2159. doi: 10.1016/j.ekir.2022.07.004. eCollection 2022 Oct.
9
Is Preemptive Kidney Transplantation Associated With Improved Outcomes when Compared to Non-preemptive Kidney Transplantation in Children? A Systematic Review and Meta-Analysis.在儿童中,与非抢先性肾移植相比,抢先性肾移植是否与改善结局相关?系统评价和荟萃分析。
Transpl Int. 2022 Mar 17;35:10315. doi: 10.3389/ti.2022.10315. eCollection 2022.
10
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.